ESSA Pharma (EPIX) Insider Trading & Ownership $1.74 +0.04 (+2.06%) As of 07/3/2025 01:01 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ESSA Pharma (NASDAQ:EPIX) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage15.50%Number OfInsiders Buying(Last 12 Months)0Number OfInsiders Selling(Last 12 Months)2Amount OfInsider Selling(Last 12 Months)$12.08M Get EPIX Insider Trade Alerts Want to know when executives and insiders are buying or selling ESSA Pharma stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address EPIX Insider Buying and Selling by Quarter ESSA Pharma Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame Start Date End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails11/1/2024Growth N. V. Biotechmajor shareholderSell7,879,583$1.53$12,055,761.99 10/7/2024Peter VirsikCOOSell694$6.03$4,184.82 9/9/2024Peter VirsikCOOSell694$6.00$4,164.00 9/3/2024Peter VirsikCOOSell2,082$6.03$12,554.46 (Data available from 1/1/2013 forward) EPIX Insider Trading Activity - Frequently Asked Questions Who is on ESSA Pharma's Insider Roster? The list of insiders at ESSA Pharma includes David Ross Parkinson, Franklin M Berger, Growth N V Biotech, and Peter Virsik. Learn more on insiders at EPIX. What percentage of ESSA Pharma stock is owned by insiders? 15.50% of ESSA Pharma stock is owned by insiders. Learn more on EPIX's insider holdings. Which ESSA Pharma insiders have been buying company stock? The following insiders have purchased EPIX shares in the last 24 months: David Ross Parkinson ($21,212.90), and Franklin M Berger ($454,274.07). How much insider buying is happening at ESSA Pharma? Insiders have purchased a total of 92,482 EPIX shares in the last 24 months for a total of $475,486.97 bought. Which ESSA Pharma insiders have been selling company stock? The following insiders have sold EPIX shares in the last 24 months: Growth N. V. Biotech ($12,055,761.99), and Peter Virsik ($58,937.13). How much insider selling is happening at ESSA Pharma? Insiders have sold a total of 7,887,552 ESSA Pharma shares in the last 24 months for a total of $12,114,699.12 sold. More Insider Trading Tools from MarketBeat Related Companies LFCR Insider Transactions AARD Insider Transactions OLMA Insider Transactions OCGN Insider Transactions GOSS Insider Transactions GLUE Insider Transactions CRVS Insider Transactions RNAC Insider Transactions ADCT Insider Transactions AVTE Insider Transactions Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles Insider Selling at NVIDIA Could Turn Into an Opportunity The Top Insider Sells From Q2: Buy, Sell, or Hold?3 Hot Trades for Insiders, But Are They Good Buys for Investors?Insiders Chase Income and Stability in American Tower—Here’s Why3 Tech Stocks With High and Rising Institutional Interest This page (NASDAQ:EPIX) was last updated on 7/4/2025 by MarketBeat.com Staff From Our PartnersSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredTop Picks for Trump’s Pro-Crypto AmericaMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredGold: Now legal tender in many statesThe perfect gold play right now? (currently under $10) Everything in the news now lines up perfectly for an...Stansberry Research | SponsoredRevealed: NEW A.I. revolution (nobody is talking about)Nvidia's CEO says this is: "The next wave of A.I." We're at the cusp of a new "A.I. Upgrade" that is set to...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ESSA Pharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ESSA Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
